A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nivolumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Hyaluronidase; Pegfilgrastim; Prednisolone; Rituximab; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use

29 May 2024 Planned End Date changed from 31 Dec 2028 to 30 Sep 2027.
29 May 2024 Planned primary completion date changed from 31 Dec 2028 to 30 Sep 2027.
26 Sep 2023 Time frame changed from up to 5 years to up to 7 years.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com